Paediatric formulations of artemisinin-based combination therapies for treating uncomplicated malaria in children

Cochrane Database of Systematic Reviews

Volumn 2020, Issue 12, 2020, Pages

  Bélard, Sabine ^a,c   Ramharter, Michael ^b   Kurth, Florian ^b,c  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c BERLIN INSTITUTE OF HEALTH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ARTEMETHER PLUS BENFLUMETOL; DIHYDROARTEMISININ PLUS PIPERAQUINE; ANTIMALARIAL AGENT; ARTEMISININ DERIVATIVE; DIHYDROARTEMISININ; PIPERAQUINE; QUINOLINE DERIVATIVE;

AFRICA SOUTH OF THE SAHARA; COMPARATIVE STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FEVER; HUMAN; LIFE THREAT; MALARIA FALCIPARUM; MAXIMUM CONCENTRATION; MORTALITY RATE; PARASITE CLEARANCE; PATIENT COMPLIANCE; PHARMACOKINETIC PARAMETERS; PLASMODIUM FALCIPARUM; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; TREATMENT FAILURE; TREATMENT OUTCOME; VOMITING; ADOLESCENT; ADVERSE EVENT; CHILD; CONFIDENCE INTERVAL; DRUG COMBINATION; INFANT; META ANALYSIS; PRESCHOOL CHILD; STATISTICAL BIAS; SUSPENSION; TABLET;

ADOLESCENT; ANTIMALARIALS; ARTEMETHER, LUMEFANTRINE DRUG COMBINATION; ARTEMISININS; BIAS; CHILD; CHILD, PRESCHOOL; CONFIDENCE INTERVALS; DRUG COMBINATIONS; HUMANS; INFANT; MALARIA, FALCIPARUM; QUINOLINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SUSPENSIONS; TABLETS; TREATMENT FAILURE; VOMITING;

EID: 84876152139     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD009568.pub2     Document Type: Review

References (28)

1. Abdulla S, Sagara I, Borrmann S, D'Alessandro U, González R, Hamel M, et al. Efficacy and safety of artemether-lumefantrine dispersible tablets compared with crushed commercial tablets in African infants and children with uncomplicated malaria: a randomised, single-blind, multicentre trial. Lancet 2008;372(9652):1819-27. x-wiley/crsRef/15482229 [DOI: 10.1016/S0140-6736(08)61492-0]
2. Bassat Q, González R, Machevo S, Nahum A, Lyimo J, Maiga H, et al. Similar efficacy and safety of artemether-lumefantrine (Coartem®) in African infants and children with uncomplicated falciparum malaria across different body weight ranges. Malaria Journal 2011;10:369. x-wiley/crsRef/15482230 [DOI: 10.1186/1475-2875-10-369]
3. Djimde AA, Tekete M, Abdulla S, Lyimo J, Bassat Q, Mandomando I, et al. Pharmacokinetic and pharmacodynamic characteristics of a new pediatric formulation of artemether-lumefantrine in African children with uncomplicated Plasmodium falciparum malaria. Antimicrobial Agents and Chemotherapy 2011;55(9):3994–9. x-wiley/crsRef/15482231 [DOI: 10.1128/AAC.01115-10]
4. Gargano N, Madrid L, Valentini G, D’Alessandro U, Halidou T, Sirima S, et al. Efficacy and tolerability outcomes of a phase II, randomized, open-label, multicenter study of a new water-dispersible pediatric formulation of dihydroartemisinin-piperaquine for the treatment of uncomplicated plasmodium falciparum malaria in African infants. Antimicrobial Agents and Chemotherapy 2018;62(1):e00596-17. x-wiley/crsRef/15482233 [DOI: 10.1128/AAC.00596-17]
5. Juma EA, Obonyo CO, Akhwale WS, Ogutu BR. A randomized, open-label, comparative efficacy trial of artemether-lumefantrine suspension versus artemether-lumefantrine tablets for treatment of uncomplicated Plasmodium falciparum malaria in children in western Kenya. Malaria Journal 2008;7:262. x-wiley/crsRef/15482235 [DOI: 10.1186/1475-2875-7-262]
6. Banek K, Webb EL, Smith SJ, Chandramohan D, Staedke SG. Adherence to treatment with artemether-lumefantrine or amodiaquine-artesunate for uncomplicated malaria in children in Sierra Leone: a randomized trial. Malaria Journal 2018;17(1):222. x-wiley/crsRef/15482237
7. Dama S, Niangaly H, Djimde M, Sagara I, Guindo CO, Zeguime A, et al. A randomized trial of dihydroartemisinin-piperaquine versus artemether-lumefantrine for treatment of uncomplicated Plasmodium falciparum malaria in Mali. Malaria Journal 2018;17(1):347. x-wiley/crsRef/15482239
8. Faye B, Ndiaye JL, Tine R, Sylla K, Gueye A, Lo AC, et al. A randomized trial of artesunate mefloquine versus artemether lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Senegalese children. American Journal of Tropical Medicine and Hygiene 2010;82(1):140-4. x-wiley/crsRef/15482241
9. Faye B, Kuete T, Kiki-Barro CP, Tine RC, Nkoa T, Ndiaye JL, et al. Multicentre study evaluating the non-inferiority of the new paediatric formulation of artesunate/amodiaquine versus artemether/lumefantrine for the management of uncomplicated Plasmodium falciparum malaria in children in Cameroon, Ivory Coast and Senegal. Malaria Journal 2012;11:433. x-wiley/crsRef/15482243
10. Kayentao K, Doumbo OK, Penali LK, Offianan AT, Bhatt KM, Kimani J, et al. Pyronaridine-artesunate granules versus artemether-lumefantrine crushed tablets in children with Plasmodium falciparum malaria: a randomized controlled trial. Malaria Journal 2012;11(1):364. x-wiley/crsRef/15482245
11. Ogutu BR, Onyango KO, Koskei N, Omondi EK, Ongecha JM, Otieno GA, et al. Efficacy and safety of artemether-lumefantrine and dihydroartemisinin-piperaquine in the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children aged less than five years: results of an open-label, randomized, single-centre study. Malaria Journal 2014;13:33. x-wiley/crsRef/15482247 [DOI: 10.1186/1475-2875-13-33]
12. Paczkowski M, Mwandama D, Marthey D, Luka M, Makuta G, Sande J, et al. In vivo efficacy of artemether-lumefantrine and artesunate-amodiaquine for uncomplicated Plasmodium falciparum malaria in Malawi. Malaria Journal 2016;15:236. x-wiley/crsRef/15482249
13. Roth JM, Sawa P, Makio N, Omweri G, Osoti V, Okach S, et al. Pyronaridine-artesunate and artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children: a randomized controlled non-inferiority trial. Malaria Journal 2018;17(1):199. x-wiley/crsRef/15482251
14. Sagara I, Beavogui AH, Zongo I, Soulama I, Borghini-Fuhrer I, Fofana B, et al. Pyronaridine–artesunate or dihydroartemisinin–piperaquine versus current first-line therapies for repeated treatment of uncomplicated malaria: a randomised, multicentre, open-label, longitudinal, controlled, phase 3b/4 trial. Lancet 2018;391(10128):1378-90. x-wiley/crsRef/15482253
15. Sirima SB, Ogutu B, Lusingu JP, Mtoro A, Mrango Z, Ouedraogo A, et al. Comparison of artesunate-mefloquine and artemether-lumefantrine fixed-dose combinations for treatment of uncomplicated Plasmodium falciparum malaria in children younger than 5 years in sub-Saharan Africa: a randomised, multicentre, phase 4 trial. Lancet Infectious Diseases 2016;16(10):1123-33. x-wiley/crsRef/15482255
16. Tahar R, Almelli T, Debue C, Foumane NV, Djaman AJ, Whegang YS, et al. Randomized trial of artesunate-amodiaquine, atovaquone-proguanil, and artesunate-atovaquone-proguanil for the treatment of uncomplicated falciparum malaria in children. Journal of Infectious Diseases 2014;210(12):1962-71. x-wiley/crsRef/15482257
17. Toure OA, Kouame MG, Didier YJ, Berenger AA, Djerea K, Genevieve GO, et al. Artesunate/mefloquine paediatric formulation vs. artemether/lumefantrine for the treatment of uncomplicated Plasmodium falciparum in Anonkoua koute, Cote d'Ivoire. Tropical Medicine & International Health 2011;16(3):290-7. x-wiley/crsRef/15482259
18. McMaster University (developed by Evidence Prime) GRADEpro GDT. Hamilton (ON): McMaster University (developed by Evidence Prime), accessed November 2019. Available at gradepro.org.
19. Higgins JP, Altman DG, Sterne JA, editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS, editor(s), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017). The Cochrane Collaboration, 2017. Available from www.training.cochrane.org/handbook.
20. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). Integrated Addendum to ICH E6(R1): Guideline for Good Clinical Practice E6(R2). Available at: https://database.ich.org/sites/default/files/E9_Guideline.pdf 2016.
21. Kurth F, Bélard S, Adegnika AA, Gaye O, Kremsner PG, Ramharter M. Do paediatric drug formulations of artemisinin combination therapies improve the treatment of children with malaria? A systematic review and meta-analysis. Lancet Infectious Diseases 2010;10(2):125-32.
22. Ranmal SR, O'Brien F, Lopez F, Ruiz F, Orlu M, Tuleu C, et al. Methodologies for assessing the acceptability of oral formulations among children and older adults: a systematic review. Drug Discovery Today 2018;23(4):830-47.
23. Nordic Cochrane Centre, The Cochrane Collaboration Review Manager 5 (RevMan 5). Version 5.4. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2020.
24. Thabet Y, Klingmann V, Breitkreutz J. Drug formulations: standards and novel strategies for drug administration in pediatrics. Journal of Clinical Pharmacology 2018;58(Suppl 10):26-35.
25. World Health Organization. Methods for surveillance of antimalarial drug efficacy. WHO Library 2009 2009. [ISBN 978 92 4 159753 1]
26. World Health Organization. Guidelines for the treatment of malaria - 3rd edition. www.who.int/malaria/publications/atoz/9789241549127/en/2015 2015. [ISBN 978 92 4 154912 7]
27. World Health Organization. World malaria report 2019. www.who.int/publications-detail/world-malaria-report-2019 2019. [ISBN 978-92-4-156572-1]
28. Bélard S, Kurth F, Ramharter M. Paediatric formulations of artemisinin-combination therapies for treating uncomplicated malaria in children. Cochrane Database of Systematic Reviews 2012, Issue 1. Art. No: CD009568. [DOI: 10.1002/14651858.CD009568]